NeoGenomics (NEO) investor relations material

Financial performance and growth drivers

• Achieved 11% year-over-year revenue growth in Q1, with clinical business up 14% and NGS representing over a third of business, growing at 26%.

• Secured reimbursement for PanTracer LBx and re-entered RaDaR ST, contributing to strong financial and strategic results.

• Focused on driving revenue and margin expansion through clarity, simplification, and internal development rather than acquisitions.

• Investments prioritized in sales, innovation, and product pipeline to sustain revenue growth and margin expansion.

• Gross margin improvements targeted through lab integration, automation, and technology upgrades like NovaSeq X.

Strategic priorities and operational focus

• Emphasis on focus and clarity to advance key initiatives and avoid spreading resources too thin.

• Shifted towards developing proprietary products, with PanTracer and RaDaR ST showing progress and new indications submitted.

• Operating leverage and efficiency improvements expected to drive adjusted EBITDA margins.

• G&A as a percent of revenue expected to decline over 18–24 months, offsetting increased investment in sales and R&D.

• Sales force expansion underway, with 25 new oncology sales specialists to be onboarded by Q3, supporting portfolio growth.

Product innovation and market adoption

• RaDaR ST relaunched with strong uptake, 29% return customers, and over a third attach rate with CGP testing.

• Most RaDaR volume from head and neck HPV negative and breast indications, with additional indications pending MolDX approval.

• PanTracer portfolio (tissue and liquid) growing rapidly, with tissue-first approach prevalent except in lung; liquid biopsy adoption accelerating.

• NGS growth rate expected to surpass last year's 22%, with sustainable outperformance anticipated.

• Differentiation strategy centers on breadth of portfolio, strong customer experience, and seamless integration with EMR systems.